Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

By Clifford R. Jack Jr., D. Dickson, J. Parisi, Yc Xu, Rh H. Cha, P. O'brien, S. Edland, G. Smith, B. F. Boeve, E. Tangalos and 2 more. Neurology, 2002

603 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/be270ac9e26c4d48388cc24759fb07cf3cb37ac2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. F. Grodstein

In Physiology

1. Clifford R. Jack Jr.
2. John C. Morris
3. Ronald C. Petersen
4. Reisa A. Sperling
5. William J. Jagust
6. Brad Boeve
7. John Q. Trojanowski
8. David S. Knopman

In Psychiatry and Mental health

1. Clifford R. Jack Jr.
2. John C. Morris
3. Ronald C. Petersen
4. Reisa A. Sperling
5. Bruce Fischl
6. William J. Jagust
7. David S. Knopman
8. John Q. Trojanowski

Citations in the corpus

• The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals (2008, background): “There was no significant thinning in the primary visual cortex (0.03 mm [2.2%], P = 0.19).”
• Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. (2005, background): “…provided by post-mortem findings in AD patients that show correlation between reduced HC volume and neurodegeneration stages (Gosche et al., 2002; Jack et al., 2002) or total number of neurons (Kril et al., 2004), the clear picture of neurobiological meaning of regional brain shrinkage will…”
• Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup (2024, positive): “174,175 Synaptic loss and dysfunction are an important feature of neurodegenerative diseases.”
• Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease (2017, background): “Indeed, NFTs appear to parallel grey matter atrophy (Jack et al., 2002; Whitwell et al., 2008), which in turn has been extensively associated with cognitive impairment.”
• Tensor-Based Morphometry as a Neuroimaging Biomarker for Alzheimer’s Disease: An MRI Study of 676 AD, MCI, and Normal Subjects (2008, positive): “…measures of cortical and hippocampal atrophy have been used in recent clinical trials (Grundman et al., 2002; Jack et al., 2003), and they have been shown to correlate with pathologically confirmed neuronal loss and with the molecular hallmarks of AD (Jack et al., 2002; Silbert et al., 2003).”
• Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) (2005, positive): “Several studies have ound a good correlation between degree of atrophy on tructural imaging and histopathologically confirmed neuon loss and AD pathology [26,34,35] and between progresion of cognitive impairment and atrophy rate [31,36].”
• Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade (2010, positive): “56 57 – 59 Additionally, the topographic distribution of atrophy on MRI maps well onto Braak’s staging of NFT pathology in patients who have undergone ante-mortem MRI and post-mortem AD staging.”